EGFR E114K

News alerts, weekly reports and conference planners

Entrez ID:

1956

Related biomarkers:

‹

›

almost2years

Landscape of EGFR Extracellular Domain Mutations in Advanced Non Small Cell Lung Carcinoma (IASLC-WCLC 2022)

This analysis describes the largest EGFR ECD mutational landscape of advanced NSCLC patients detected via ctDNA. EGFR ECD mutations in NSCLC do not appear to be mutually exclusive with other oncogenic driver mutations, and further evaluation of biological and clinical relevance is warranted.

almost 2 years ago

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • KRAS Q61H • EGFR E114K • ALK-ROS1 fusion • EGFR A289V

Guardant360® CDx

3years

Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report. (PubMed, Medicine (Baltimore))

This case report demonstrates that EGFR-ZNF880 fusion and EGFR E114K mutations may contribute or lead to the formation of a special HER2 dimer, which is rapidly resistant to lapatinib but sensitive to pyrotinib. Of note, this is the first report that such a new fusion has been found.

3 years ago

Clinical • Journal

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive • EGFR mutation • HER-2 overexpression • HER-2 amplification • EGFR positive • EGFR E114K

Herceptin (trastuzumab) • lapatinib • Irene (pyrotinib)